Stryker (SYK) DIvidends Date & History

Key Takeaways

• SYK pays a quarterly dividend of $0.88 per share, or roughly $3.52 annually, for a dividend yield of approximately 1.1%.
• The company has raised its dividend for 32 consecutive years, with a five-year average annual increase of about 7.6%.
• The payout ratio is roughly 36% of trailing earnings and about 23% of free cash flow (FCF), leaving ample room for future increases.
• Stryker is best described as a dividend growth stock rather than a high-yield income stock.
• The next ex-dividend date is September 30, 2026, with payment scheduled for October 30, 2026.

Dividend Overview

Stryker Corporation, a leading medical technology company, maintains a disciplined but modest dividend policy. The company pays its dividend quarterly, with a current quarterly rate of $0.88 per share — equivalent to an annualized payout of about $3.52 per share. At recent share prices, this translates to a dividend yield of roughly 1.1%, well below the broader healthcare sector average.

Stryker is not a high-yield stock; instead, it is a classic dividend growth stock. The company prioritizes reinvesting its substantial free cash flow into research and development, acquisitions, and product innovation, while still returning a steadily rising portion of profits to shareholders. For investors, the appeal lies less in the current income stream and more in the consistency and growth of that stream over time.

Dividend History and Growth

Stryker has a long track record of dependable dividend increases. The company has raised its dividend for 32 consecutive years, a streak that places it among the more consistent dividend growers in the medical device industry. In December 2025, Stryker increased its quarterly dividend from $0.84 to $0.88 per share, a rise of roughly 5%.

Looking back, the annual dividend has climbed from about $2.59 per share in 2021 to approximately $3.52 per share today. Over the past five years, the dividend has grown at an average annualized rate of around 7.6%. This steady, mid-single-digit growth reflects management's long-term commitment to returning capital to shareholders while funding ongoing expansion.

Dividend Sustainability and Payout Ratio

Stryker's dividend appears highly sustainable. Based on trailing twelve-month earnings, the payout ratio is approximately 36%, meaning the company distributes only a little more than a third of its net income as dividends. Measured against free cash flow (FCF) — the cash a company generates after capital spending — the payout is even more conservative at roughly 23%.

This financial cushion is supported by strong fundamentals. Stryker generates free cash flow of about $3.5 billion annually, giving management significant flexibility to fund the dividend, pursue acquisitions, and reinvest in the business. The company carries moderate leverage, with a debt-to-equity ratio in the mid-60% range, which is typical for a large-cap medical technology firm. Earnings per share (EPS) comfortably covers the dividend several times over, providing a wide margin of safety for income investors.

Dividend Compared to Industry Peers

Within the medical device and healthcare sector, Stryker's yield sits on the lower end of the range, reflecting its growth-oriented profile. Diversified healthcare giant JNJ (Johnson & Johnson) and medtech peer MDT (Medtronic) typically offer yields around 3%, while ABT (Abbott Laboratories) yields roughly 2%. By contrast, orthopedic-focused ZBH (Zimmer Biomet) yields around 0.9%, and BSX (Boston Scientific) pays no dividend at all.

Stryker's roughly 1.1% yield therefore ranks below higher-yielding healthcare names but above several faster-growing device makers. The trade-off is clear: Stryker offers a lower current yield in exchange for a long, uninterrupted dividend growth streak and greater reinvestment in its business.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is particularly useful for identifying dividend stocks, income-focused investments, trending stocks, and breakout candidates far more efficiently than manual screening. Explore the AI Screener to uncover dividend opportunities and income-focused ideas that match your criteria.

Is This Stock Attractive for Dividend Investors?

Stryker is likely to appeal most to dividend growth investors and long-term, total-return-oriented investors rather than those seeking immediate high income. Its yield of about 1.1% is modest, so investors who depend primarily on current dividend income may find other healthcare names more suitable.

However, for investors focused on the long game, Stryker's profile is compelling: 32 consecutive years of dividend increases, a conservative payout ratio, strong free cash flow, and a dominant position in high-demand areas such as orthopedics, medical and surgical equipment, and neurotechnology. This combination suggests the dividend has room to keep growing. The stock is best suited to patient investors willing to accept a lower current yield in exchange for dependable, compounding dividend growth and exposure to a well-capitalized medical technology leader. As always, individual suitability depends on personal goals, time horizon, and risk tolerance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations